RBC Capital Maintains Outperform on Elevance Health, Lowers Price Target to $478
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Elevance Health but lowers the price target from $585 to $478.
October 18, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Outperform rating on Elevance Health but has lowered the price target from $585 to $478, indicating a more conservative outlook.
The maintenance of an Outperform rating suggests continued confidence in Elevance Health's performance, but the lowered price target indicates a more cautious outlook, likely due to changes in market conditions or company performance. This could lead to a short-term negative impact on the stock price as investors adjust expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100